- Home
- WALD vs KZIA Comparison
WALD vs KZIA Comparison
Compare WALD & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WALD | KZIA |
|---|---|---|
| Founded | 1988 | 1994 |
| Country | United Kingdom | Australia |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.3M | 186.7M |
| IPO Year | 2021 | 2002 |
Fundamental Metrics
Financial Performance| Metric | WALD | KZIA |
|---|---|---|
| Price | $1.13 | $10.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.00 | ★ $19.50 |
| AVG Volume (30 Days) | 257.3K | ★ 293.3K |
| Earning Date | 03-13-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.89 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $4.86 |
| 52 Week High | $3.22 | $17.40 |
Technical Indicators
Market Signals| Indicator | WALD | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 27.58 | 35.49 |
| Support Level | $0.86 | $5.15 |
| Resistance Level | $1.18 | $10.49 |
| Average True Range (ATR) | 0.07 | 1.15 |
| MACD | -0.01 | -0.32 |
| Stochastic Oscillator | 16.67 | 2.15 |
Price Performance
Historical ComparisonAbout WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.